重症联合免疫缺陷病发病机制和基因治疗的进展_肖生祥-2002.pdfVIP

2002 282 79 58-63. 16 LeMaistre CF, Saleh MN, Kuzel TM, et al.Phase I trial of a ligand fu- 9 Kuzel TM, Hurria A, Samuelson E, et al.Phase II trial of 2- sion-protein (DAB389IL-2)in lymphomas e pressing the receptor for in- chlorodeo yadenosine for the treatment of cutaneous T-cell lymphoma. terleukin-2.Blood, 1998,91(2):399-405. Blood, 1996,87(3):906-911. 17 Saleh MN, LeMaistre CF, Kuzel TM, et al.Antitumor activity of 10 Zinzani PL, Baliva G, Magagnoli M, et al.Gemcitabine treatment in pre- DAB389IL-2 fusion to in in mycosis fungoides.J Am Acad Dermatol, treated cutaneous T-cell lymphoma:e perience in 44 patients.J Clin On- 1998, 39(1):63-73. col, 2000 , 18(13):2603-2606. 18 Olsen E, Duvic M, Frankel A, et al.Pivotal phase III trial of two dose 11 Siegel RS, Pandolfino T, Guitart J, et al.Primary cutaneous T-cell lym- levels of denileukin diftito for the treatment of cutaneous T-cell lym- phoma:review and current concepts.J Clin Oncol, 2000, 18 (15 ):2908- phoma.J Clin Oncol, 2001, 19(2):376-388. 2925. 19 Kno S, Hoppe RT, Maloney D, et al.Treatment of cutaneous T-cell lym- 12 Henney JE.From the Food and Drug Administration.JAMA, 2000 , 283 phoma with chimeric anti-CD4 monoclonal antibody.Blood, 1996, 87(3): (9):1131. 893-899. 13 Jumbou O, NGuyen JM, Tessier MH, et al.Long-term follow-up in 51 20 Pawson R, Dyer MJ, Barge R, et al.Treatment of T-cell prolymphocytic patients with mycosis fungoides and Sezary syndrome treated by interferon- leukemia with human CD52 antibody.J Clin Oncol, 1997, 15 (7):2667- alfa.Br J Dermatol, 1999, 140(3):427-431. 2672. 14 Rook AH, Wood GS, Yoo EK, et al.Interleukin-12 therapy of cutaneous 21 Lundin J, Osterborg A, Brittinger G, et al.CAMPATH-1H monoclonal an- T-cell lymphoma induces lesion regression and